What's the difference between Ozempic, Wegovy, and Rybelsus?
Ozempic, Wegovy, and Rybelsus all contain semaglutide. They differ in form, FDA indication, dose ceiling, and how insurance covers them.
Updated May 25, 2026 · 4 min read
All three are semaglutide — same active molecule, same manufacturer (Novo Nordisk). The differences are the form of the drug, the FDA-approved indication, the dose ceiling, and therefore how insurance covers them.
The At-a-Glance Table
| Ozempic | Wegovy | Rybelsus | |
|---|---|---|---|
| Active drug | Semaglutide | Semaglutide | Semaglutide |
| Form | Weekly injection (pen) | Weekly injection (pen) | Daily oral tablet |
| FDA indication | Type 2 diabetes | Chronic weight management | Type 2 diabetes |
| Dose range | 0.25 → 2 mg weekly | 0.25 → 2.4 mg weekly | 3, 7, or 14 mg daily |
| Approved population | Adults with T2D | Adults with BMI ≥ 30, or ≥ 27 + comorbidity | Adults with T2D |
| Cardiovascular indication | Yes (SELECT, 2023) | Not yet labeled | No |
| Insurance coverage | Usually with T2D Dx | Varies; often harder to get | Usually with T2D Dx |
Ozempic
Ozempic is the semaglutide injection approved for type 2 diabetes. It comes in a prefilled pen; you inject once per week. The approved dose ceiling is 2 mg weekly.
Ozempic is one of the most prescribed medications in the US and has been on the market since 2017. It also carries the SELECT cardiovascular indication — a labeled use for reducing the risk of major adverse cardiovascular events in adults with established cardiovascular disease and either overweight or obesity, regardless of diabetes status. That SELECT indication was added to the label in 2023 based on the SELECT trial.
Many people take Ozempic off-label for weight management. Clinicians frequently prescribe it this way because it's been on the market longer, is more familiar, and is often more accessible (especially before Wegovy's supply stabilized).
Wegovy
Wegovy is the semaglutide injection approved specifically for chronic weight management. Same pen, same molecule, slightly higher maximum dose (2.4 mg vs Ozempic's 2 mg). It's approved for adults with BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, sleep apnea, prediabetes, dyslipidemia).
The titration schedule is identical to Ozempic's through 2 mg, then adds one more step to 2.4 mg.
The insurance distinction: Wegovy has a weight management indication, which commercial insurance and Medicare Part D cover inconsistently. Many commercial plans now cover it; Medicare Part D recently gained authority to cover weight-loss drugs for certain high-cardiovascular-risk populations. But coverage gaps remain, especially for Medicaid and some employer-sponsored plans. Ozempic, prescribed for diabetes, generally has better insurance coverage — which is one reason so much off-label prescribing happens.
Rybelsus
Rybelsus is oral semaglutide — the same molecule in a daily tablet. It's approved for type 2 diabetes, not weight management.
The dose numbers look dramatically different (3, 7, 14 mg) compared to the injectable (0.25–2.4 mg) because oral bioavailability of semaglutide is only about 1%. The stomach's acid and digestive enzymes break down most of the peptide before it can be absorbed. Rybelsus includes an absorption enhancer (sodium N-caprate) that helps, but you still need a much higher dose to get a therapeutic blood level.
Rybelsus must be taken:
- On a completely empty stomach (no food, water, or other medications for 30 minutes after)
- With just a small sip of plain water (no more than 4 oz)
- First thing in the morning
Deviating from these rules significantly reduces absorption. The restrictions make it less convenient than the weekly injection for many patients.
Weight loss on Rybelsus is real but generally less than the injections — partly because the effective blood levels are lower, and partly because the GI tolerability issues that limit dose aren't fully escaped.
Which One Is Right for You?
That's a conversation for your prescriber, but the basic logic:
- Type 2 diabetes, need prescription covered: Ozempic or Rybelsus, depending on injection comfort
- Weight management, don't have T2D: Wegovy (with Ozempic as a common off-label alternative)
- Strong preference to avoid injections: Rybelsus — with the expectation that weight loss will be more modest
- Established cardiovascular disease + overweight: Ozempic (the SELECT indication specifically covers this)
The active drug is identical, so switching between Ozempic and Wegovy involves nothing more than a new prescription — there's no titration reset needed if you're at the same dose level.